Abstract
Objective Lipid management is one of the cornerstones of cardiovascular risk reduction. Treatment of HIV infection with protease inhibitors (PIs) may cause dyslipidaemia, whilst the integrase inhibitor raltegravir (RAL) has a relatively favorable effect on plasma lipids. We examined the effect of switching from PIs to RAL on endothelial function, and its effect on immunological and inflammatory parameters. Methods We performed a 16-week open-label prospective crossover study: 8 weeks intervention (switch PIs to RAL) and 8 weeks control (unchanged cART regimen). Flow-mediated dilatation (FMD), inflammatory plasma, and cellular markers of immune activation were measured at weeks 0, 8, and 16. Results Study participants (n = 22) with a median age of 50 years (IQR 42-60) and known HIV infection of 6.5 years (IQR 5.0-17.3) were on stable cART with undetectable HIV viral loads. After 8 weeks of RAL therapy, a reduction in FMD of -0.81% was seen, compared to +0.54% control (pairwise, p = 0.051), while fasting total cholesterol (-17% versus +10%; p < 0.001), LDL cholesterol (-21% versus -3%; p = 0.026), and triglycerides (-41% versus +18%; p = 0.001) significantly decreased during RAL therapy compared to the control. Furthermore, a rel...Continue Reading
References
Nov 7, 1992·Lancet·D S CelermajerJ E Deanfield
Jul 18, 2001·Circulation·J H SteinJ M Sosman
May 9, 2002·Atherosclerosis·E SeminariS Testa
Dec 1, 2004·Circulation·Kwang Kon KohEak Kyun Shin
Mar 12, 2005·The Journal of Antimicrobial Chemotherapy·Maria Luisa MontesJose R Arribas
May 3, 2006·The Journal of Infectious Diseases·Jessica R GrubbMark T Gladwin
Sep 28, 2006·The Journal of Clinical Endocrinology and Metabolism·Stine JohnsenSteve Grinspoon
Apr 27, 2007·The New England Journal of Medicine·UNKNOWN DAD Study GroupJens D Lundgren
Jul 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael P DubéKieren J Mather
Jan 16, 2010·Lancet·Joseph J EronUNKNOWN SWITCHMRK 1 and 2 investigators
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kenneth A LichtensteinUNKNOWN HIV Outpatient Study (HOPS) Investigators
Jul 6, 2010·Atherosclerosis·Remy H H BemelmansFrank L J Visseren
Jan 12, 2011·The Journal of Experimental Medicine·Daniel O GriffinThomas L Rothstein
Mar 16, 2011·The Journal of Infectious Diseases·Hiroyu HatanoSteven G Deeks
Sep 16, 2011·The Journal of Infectious Diseases·Tricia H BurdoSteven Grinspoon
Feb 1, 2012·Antiviral Therapy·Josep M LlibreBonaventura Clotet
Mar 15, 2012·HIV Medicine·F M IslamD P Wilson
Mar 30, 2012·European Journal of Preventive Cardiology·Eli-Anne SkaugOyvind Ellingsen
Apr 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerUNKNOWN AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis
Oct 9, 2012·International Journal of Cardiology·Rouyanne T RasPeter L Zock
Oct 19, 2012·The Journal of Antimicrobial Chemotherapy·Mar MasiáFélix Gutiérrez
Nov 2, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Dimitrios TsiantoulasChristoph J Binder
Nov 2, 2014·The Journal of Infectious Diseases·Rebeccah A McKibbenWendy S Post
Jan 13, 2015·Lancet·UNKNOWN Cholesterol Treatment Trialists' (CTT) CollaborationAnthony Keech
Jan 15, 2015·The Journal of Infectious Diseases·Corrilynn O HilemanGrace A Mccomsey
Apr 24, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Theodoros KelesidisGrace A McComsey
Sep 16, 2015·AIDS·James H SteinJudith S Currier
Jun 15, 2016·Infectious Diseases and Therapy·Maaike KrikkeAndy I M Hoepelman